Arcadia Biosciences Announces $14.0 Million Registered Direct Offering Priced At-the-Market
Arcadia intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, scale-up of its GoodWheat™ Resistant Starch wheat production, early commercialization activities, continued research and development activities and for general and administrative expenses.
The shares of common stock (but not the warrants or the shares of common
stock underlying the warrants) are being offered by Arcadia pursuant to
a "shelf" registration statement on Form S-3 that was filed on
A final prospectus supplement and accompanying base prospectus relating
to the shares of common stock being offered will be filed with the
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the proposed
offering and the anticipated use of proceeds therefrom, the completion
and size of the registered direct offering, including, without
limitation, market conditions and the satisfaction of closing conditions
related to the registered direct offering; the company’s and its
partners’ and affiliates’ ability to identify and isolate desired
traits; the demand for the company’s products, both from commercial
partners and consumers; the company’s and its partners’ ability to
develop commercial products incorporating its traits and complete the
regulatory review process for such products; the company’s compliance
with laws and regulations that impact the company’s business, and
changes to such laws and regulations; the company’s future capital
requirements and ability to satisfy its capital needs; and the other
risks set forth in the company’s filings with the
Arcadia Biosciences, Inc.
Jeff Bergau, +1-312-217-0419